Isolated peptides
Specific tripeptides disrupt AtaA polypeptide self-aggregation and separate binding with targets, addressing the challenges of controlling microbial immobilization and enhancing bioprocess efficiency.
Patent Information
- Application Number
- JP2021533118
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-18
- Filing Date
- 2020-07-17
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-07-17
AI Technical Summary
Existing technologies face challenges in disrupting the self-aggregation of AtaA polypeptides and dissociating their binding with other targets, such as streptavidin, which is crucial for controlling bioprocesses and immobilizing microorganisms on surfaces.
The use of specific tripeptide sequences, including AVL, SVL, and ATL, or functionally equivalent peptides, to disrupt self-aggregation of AtaA polypeptides and separate their binding with other targets like streptavidin, achieved through the introduction of adhesion-imparting DNA and subsequent peptide treatment.
The peptides effectively inhibit self-aggregation and separate binding, enabling the controlled attachment and detachment of microorganisms from carriers, facilitating bioprocess control and reuse of cells and carriers, and are applicable in industries like fermentation, pharmaceuticals, and material engineering.
Smart Images

Figure 0007577336000001 
Figure 0007577336000002 
Figure 0007577336000003
Abstract
Description
[Technical field]
[0001] The present disclosure relates to peptides that disrupt the self-aggregation of an adhesive polypeptide, the AtaA polypeptide, or a modified sequence thereof or a fragment thereof that has self-aggregation properties, and uses thereof.Furthermore, the present disclosure relates to peptides that disrupt the binding between the AtaA polypeptide or the AtaA polypeptide and other targets, such as streptavidin, and uses thereof. [Background technology]
[0002] Acinetobacter sp. Tol5 is a non-pathogenic Gram-negative bacterium that exhibits high cell self-aggregation and high adhesion to various material surfaces, from hydrophobic plastic carriers to hydrophilic glass and metal surfaces. The present inventors discovered novel bacterio-nanofibers present on the bacterial cell surface as a factor that brings about such adhesive properties, which have not been reported in other microorganisms, and further identified a new protein that constitutes the nanofibers. This protein belongs to the trimeric autotransporter adhesin (TAA) family of Gram-negative bacteria, and the present inventors named it AtaA (Non-Patent Document 1).
[0003] AtaA is extremely useful for immobilizing microorganisms, and is expected to be applied to various bioprocesses (see, for example, Patent Documents 1 and 2). In addition, in a previous patent application (Patent Document 3), the present inventors reported that various functional peptides and proteins can be introduced into AtaA and displayed on the surface of microorganisms. In Patent Document 1, AtaA and the gene encoding it (ataA gene) were called AadA and aadA gene, respectively. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Publication No. 2009 / 104281 Brochure [Patent Document 2] International Publication No. 2014 / 156736 Brochure [Patent Document 3] International Publication No. 2015 / 030171 Brochure [Non-patent literature]
[0005] [Non-Patent Document 1] Ishikawa, M.;Nakatani,H.;Hori,K.,AtaA,a new member of the trimeric autotransporter adhesins from Acinetobacter sp. Tol 5 mediating high ad hesiveness to various abiotic surfaces.PLoS One 2012,7,(11),e48830. [Non-Patent Document 2] Linke, D.; Riess, T.; Autenrieth, IB; Lupas, A.; Kempf, VA, Trimeric autotransporter adhesins: variable structure, common function. Trends Microbiol. 2006, 14, (6), 264-270. Summary of the Invention [Means for solving the problem]
[0006] As a result of intensive research, the present inventors have found that a specific tripeptide sequence disrupts the self-aggregation of the AtaA polypeptide or disrupts the binding between an AtaA polypeptide fragment and another target.
[0007] Thus, the present disclosure provides: (1) A peptide containing the amino acid sequence AVL, SVL or ATL, or a functionally equivalent sequence thereof. (2) A peptide consisting of the amino acid sequence AVL, SVL or ATL, or a functionally equivalent sequence thereof. (3) A peptide according to any one of the above items, which has the function of disrupting the self-aggregation of a polypeptide having the amino acid sequence set forth in SEQ ID NO: 4 or a modified sequence or fragment thereof having self-aggregation properties. (4) A peptide according to any one of the above items, which has the function of disrupting aggregation of cells expressing a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4 or a modified sequence thereof, or a fragment thereof. (4B) A method for attaching and detaching a microorganism, comprising: (1) a step of contacting a microorganism having nonspecific adhesiveness imparted or enhanced by the introduction of a DNA encoding an autotransporter adhesin derived from an Acinetobacter microorganism, for example, the amino acid sequence shown in SEQ ID NO: 4 or a modified sequence thereof, or a fragment thereof, with a carrier, thereby attaching the microorganism to the carrier; and (2) a step of washing the carrier to which the microorganism is attached in the presence of a peptide described in any of the above items, thereby detaching the microorganism from the carrier. (5) A peptide according to any of the above items, which has the function of separating the bond between a polypeptide comprising the amino acid sequence shown in SEQ ID NO:1 or a modified sequence thereof, or a fragment thereof, or a fusion or complex of said polypeptide with another amino acid sequence, and another target. (6) A composition comprising a peptide according to any one of the preceding items for disrupting the self-aggregation of a polypeptide having the amino acid sequence set forth in SEQ ID NO: 4 or a modified sequence or fragment thereof having self-aggregation properties. (7) A composition comprising a peptide or an analogous peptide described in any of the above items for separating the binding between a polypeptide comprising the amino acid sequence shown in SEQ ID NO:1 or a modified sequence thereof or a fragment thereof, or a fusion or complex of said polypeptide with another amino acid sequence, and another target. (8) The composition according to any of the preceding items, wherein the object is a functionality-imparting entity. (9) The composition according to any one of the preceding items, wherein the target substance is streptavidin, neutral avidin, or a modified form thereof. (10) The composition according to any of the preceding items, wherein the functionality-imparting entity is a cell. (11) A fusion or complex of the peptide according to any of the above items with a functional entity. (12) Use of a peptide according to any of the preceding items for disrupting the self-aggregation of a polypeptide having the amino acid sequence set forth in SEQ ID NO: 4 or a modified sequence or fragment thereof having self-aggregation properties. (13) Use of a peptide or a similar peptide described in any of the above items to separate the binding between a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1 or a modified sequence thereof, or a fragment thereof, or a fusion or complex of said polypeptide with another amino acid sequence, and another target. (14) The use according to any of the preceding items, wherein the object is a functionality-imparting entity. (15) The use according to any one of the preceding items, wherein the target substance is streptavidin, neutral avidin, or a modified form thereof.
[0008] It is contemplated that the present disclosure may provide one or more of the above features in combinations other than those specifically described. Still further embodiments and advantages of the present disclosure will be recognized by those skilled in the art upon reading and understanding the following detailed description, if necessary. Effect of the Invention
[0009] Using the present disclosure, it has become possible to disrupt the self-aggregation of AtaA polypeptides and fragments thereof. Thus, the peptide of the present disclosure can inhibit the layered adhesion caused by the self-aggregation of AtaA polypeptides, and is therefore useful, for example, in situations where layered adhesion is undesirable. Furthermore, the peptide of the present disclosure can separate the binding of AtaA polypeptide fragments to other targets (e.g., functional peptides such as streptavidin and neutral avidin), and is useful for controlling the on / off of processes in bioprocesses in technical fields such as fermentation industry, pharmaceutical industry, chemical industry, regenerative medicine, cell engineering, medical engineering, and biosensors, as well as in material engineering processes such as surface modification and material design. In addition, the peptide of the present disclosure can separate cells (including microorganisms and biofilms) expressing AtaA polypeptides that are fixed to a support from the support, making it possible to adjust the thickness of the biofilm in a biofilm reactor, or to separate the cells from the attached or fixed state, thereby allowing the cells and carriers to be reused. Furthermore, the peptides of the present disclosure can also be used as a means for isolating the N-terminal Nhead domain from the AtaA protein expressed on the cell membrane of Acinetobacter. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 shows still images of the collapse of the aggregates of Acinetobacter sp. Tol5 strain taken by a microscope. A shows a micrograph of the case where the BS-N medium not containing the peptide of the present disclosure is fed to the adherent aggregates of Acinetobacter sp. Tol5 strain, B shows a still image of the case where 0.1 mM AVL peptide is added to Acinetobacter sp. Tol5 strain, C shows a still image of the case where 0.1 mM ATL peptide is added, and D shows a still image of the case where 0.1 mM SVL peptide is added. All the photographs are still images taken within 10 seconds after the medium containing the peptide (blank medium not containing peptide for A) is fed. [Figure 2A]Figure 2 shows that the binding between E. coli recombinant Nhead and streptavidin is disrupted by the peptide of the present disclosure. Figure 2A shows the result of adding AVL peptide. The vertical axis of the graph shows the abundance ratio (volume %) of each particle, and the horizontal axis shows the particle diameter (nm). Note that the peaks of Nhead and SA overlap after adding the peptide. [Figure 2B] Figure 2 shows that the binding between E. coli recombinant Nhead and streptavidin is disrupted by the peptide of the present disclosure. Figure 2B shows the results of adding ATL peptide. The vertical axis of the graph shows the abundance ratio (volume %) of each particle, and the horizontal axis shows the particle diameter (nm). Note that the peaks of Nhead and SA overlap after adding the peptide. [Figure 2C] Figure 2 shows that the binding between E. coli recombinant Nhead and streptavidin is disrupted by the peptide of the present disclosure. Figure 2C shows the result of adding SVL peptide. The vertical axis of the graph shows the abundance ratio (volume %) of each particle, and the horizontal axis shows the particle diameter (nm). Note that the peaks of Nhead and SA overlap after adding the peptide. [Diagram 3] FIG. 3 shows the immobilization of biotinylated molecules using the bond between Nhead and streptavidin. The graph shows the results of detection by fluorescence of biotinylated molecules. The vertical axis of the graph shows the fluorescence intensity at 535 nm, and the horizontal axis shows, from the left, the fluorescence intensity when Nhead is not immobilized, after the first binding reaction, after the first separation reaction, after the second binding reaction, after the second separation reaction, and after the third binding reaction. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] The present disclosure will be described below while showing the best mode. Throughout this specification, the expression of the singular form should be understood to include the concept of the plural form, unless otherwise specified. Therefore, the singular article (for example, in the case of English, "a", "an", "the", etc.) should be understood to include the concept of the plural form, unless otherwise specified. In addition, it should be understood that the terms used in this specification are used in the sense commonly used in the field, unless otherwise specified. Therefore, unless otherwise defined, all technical terms and scientific and technical terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. In case of conflict, the present specification (including definitions) will take precedence.
[0012] The following provides definitions of terms particularly used in this specification and / or explains basic technical content as appropriate.
[0013] (Definition of terms) As used herein, the terms "adhere" and "adhesion" and "immobilize" and "immobilization" are used interchangeably and in the sense commonly used in the art, meaning to make at least a portion of the object of "adhesion" or "immobilization" immobilize, at least relatively, from a fixed position on the object to which it is adhered or immobilized.
[0014] In this specification, "aggregate" is used in the sense that it is usually used in the technical field, and means that a polypeptide or cell, etc. in a dispersed state gathers in a mass with the polypeptide itself or with other polypeptides or cells, etc. In particular, when the same type of polypeptide chain aggregates with each other, it is said to be "self-aggregated". For example, in the case of AtaA, a phenomenon occurs in which a mass of AtaA polypeptides or cells is formed by self-aggregation between multiple AtaAs or cells expressing AtaA, so it can be said that AtaA has a self-aggregation ability. It has been revealed in the present disclosure that the peptide of the present disclosure can disrupt the self-aggregation between AtaAs or cells expressing AtaA. For example, the use of the peptide of the present disclosure is advantageous in situations where layered adhesion is not preferable because layered adhesion is not performed by using the peptide of the present disclosure.
[0015] In addition, the use of AtaA polypeptide that maintains adhesion while preventing self-aggregation is useful in the following applications. That is, the peptide of the present disclosure can disperse cell aggregates such as those of microorganisms by disrupting self-aggregation between AtaAs. Therefore, it can be used in applications such as peeling and washing biofilms in biofilm reactors, and is useful in the fermentation industry and biofuel production. Furthermore, the peptide of the present disclosure is useful for controlling the function of a functionalization entity in bioprocesses in technical fields such as the fermentation industry, pharmaceutical industry, chemical industry, regenerative medicine, cell engineering, medical engineering, and biosensors, and in material engineering processes such as surface modification and material design, by controlling the on / off of the bond between an AtaA polypeptide fragment (particularly a fragment that has lost its cohesiveness but maintains its adhesiveness) and a functionalization entity.
[0016] As used herein, "bind" or "bound" is used in the sense commonly used in the art, and refers to a physical or chemical association between two substances or a combination thereof. In particular, in the present disclosure, the interaction between an AtaA polypeptide and streptavidin, neutral avidin, or a modified form thereof, etc., corresponds to "binding" as used herein. As used herein, "binding" corresponds to a specific interaction, and is therefore also referred to as "specific binding." On the other hand, "adhesion" or "fixation" is due to a non-specific interaction.
[0017] As used herein, the terms "separation" and "separate" are used in the sense commonly used in the art, and refer to the release of at least a portion of the "bonded" state between two or more substances that are in a "bonded" state.
[0018] As used herein, the term "disintegration" or "disintegrate" is used in the sense commonly used in the art, and means that at least a portion of the "aggregated" state between two or more substances that are in an "aggregated" state is released.
[0019] As used herein, "AtaA" refers to a protein belonging to the trimeric autotransporter adhesin (TAA) family of Gram-negative bacteria. In this specification, when "AtaA", "AtaA polypeptide", "AtaA polypeptide variant" and "AtaA polypeptide or fragment thereof" are mentioned, unless otherwise specified, it includes not only the full-length AtaA polypeptide, but also variants and fragments of AtaA polypeptide having either or both of self-aggregation and binding ability to other targets. AtaA usually has adhesion ability. AtaA forms a homotrimer and has a domain group structure arranged in the order of signal peptide-Nhead-Nstalk-Chead-Cstalk-membrane anchor from the amino terminus to the carboxy terminus. Each domain group is connected by a structure such as neck or coiled coil. Furthermore, Nhead, Nstalk, Chead, and Cstalk contain various domains such as Ylhead, Trp-ring, GIN, and FGG, and some domains are repeated. Each domain is connected by a structure such as neck or coiled coil. The full-length amino acid sequence and nucleic acid sequence of AtaA are shown in SEQ ID NOs: 4 and 3, respectively. The amino acid sequence and nucleic acid sequence of an AtaA fragment sequence that does not contain a signal peptide at the N-terminus and contains methionine at the beginning are shown in SEQ ID NOs: 1 and 2, respectively. In SEQ ID NOs: 1 and 2, Nhead (including Neck) corresponds to amino acid positions 2 to 258 and nucleic acid positions 4 to 774, Nstalk corresponds to amino acid positions 259 to 2846 and nucleic acid positions 775 to 8538, Chead (excluding Neck) corresponds to amino acid positions 2855 to 3093 and nucleic acid positions 8563 to 9279, and Cstalk (including the β-barrel-containing portion) corresponds to amino acid positions 3094 to 3518 and nucleic acid positions 9280 to 10554. Furthermore, the Nhead domain contains two loop structures that are involved in adhesion and coagulation and are necessary for binding to functional entities; these loop structures correspond to amino acids 22-50 and 161-175, and nucleic acids 64-150 and 481-525, respectively.
[0020] As used herein, "Acinetobacter" refers to the genus Acinetobacter in biological classification. The genus Acinetobacter typically includes Acinetobacter sp. Tol5 strain. Acinetobacter sp. Tol5 strain is a strain having toluene decomposition ability isolated from an exhaust gas treatment reactor, and is available from the Hori Katsutoshi Laboratory, Nagoya University. The AtaA polypeptide or a fragment thereof in the present disclosure includes, but is not limited to, those produced by Acinetobacter sp. Tol5 strain belonging to the genus Acinetobacter.
[0021] As used herein, the term "functionalizing entity" is used in the sense commonly used in the technical field, and means an entity having any function or action. The functionalizing entity is bound by the AtaA polypeptide or a fragment thereof in the present disclosure, and its function or action is typically various functions or actions useful in bioprocesses in technical fields such as pharmaceutical industry, chemical industry, regenerative medicine, cell engineering, medical engineering, biosensors, and material engineering processes such as surface modification and material design, and the like, including, but not limited to, labeling functions. In one embodiment, the functionalizing entity is a protein and / or peptide, or a cell, part thereof, biological tissue or organ, or part thereof, containing the same. In a specific embodiment, the functionalizing entity is streptavidin, neutral avidin, or a modified form thereof.
[0022] In this specification, the term "streptavidin" is used in the sense commonly used in the art, and refers to streptavidin produced by the genus Streptomyces, or its variants, derivatives, or equivalents. Examples of its amino acid sequence include, but are not limited to, those identified by P22629-1 and its nucleic acid sequence by X03591. In this specification, "streptavidin" typically binds to biotin with high affinity. In this specification, "neutral avidin" is used in the same sense as "neutra(a)vidin" and the like, and refers to a modified avidin (particularly a deglycosylated avidin) that has a pI value near neutrality and suppresses nonspecific binding. "Neutral avidin" also typically binds to biotin with high affinity. "Streptavidin" and "neutral avidin" have the property of specifically binding to the AtaA polypeptide or a fragment thereof in this disclosure.
[0023] As used herein, a "corresponding" amino acid or nucleic acid or portion refers to an amino acid or nucleotide in a polypeptide or polynucleotide molecule (e.g., AtaA, etc.) that has or is predicted to have the same action as a specific amino acid or nucleotide or portion in a polypeptide or polynucleotide that is used as a reference for comparison, and in particular in adhesive polypeptides, refers to an amino acid that is present at a similar position in a site required for adhesion or self-aggregation and contributes to adhesiveness in a similar manner. For example, in the case of an antisense molecule, it may be a similar portion in an orthologue that corresponds to a specific portion of the antisense molecule. The corresponding amino acid may be, for example, a specific amino acid that is cysteinized, glutathionylated, formed with an SS bond, oxidized (e.g., oxidized at the methionine side chain), formylated, acetylated, phosphorylated, glycosylated, myristylated, or the like. Alternatively, the corresponding amino acid may be an amino acid that is responsible for trimerization. Such a "corresponding" amino acid or nucleic acid may be a region or domain that spans a certain range. Therefore, in such a case, it is referred to as a "corresponding" region or domain in this specification.
[0024] As used herein, "fusion" means that two or more molecules (e.g., polypeptides or nucleic acids) or portions thereof are covalently linked. When two or more portions are polypeptides and are covalently linked, the result of "fusion" is a fusion product or fusion product, or a fusion protein or fusion polypeptide, which may also be called a chimeric polypeptide. In the case of a polypeptide fusion, a nucleic acid fusion is usually created by linking the base sequences of nucleic acids encoding two types of polypeptides, and the fusion polypeptide is produced as a recombinant protein using the nucleic acid fusion as a blueprint.
[0025] As used herein, the term "complex" is used in the sense commonly used in the art, and refers to any construct containing two or more parts. For example, when one part is a polypeptide, the other part may be a polypeptide or other substances (e.g., sugars, lipids, nucleic acids, other carbohydrates, etc.). As used herein, the two or more parts constituting a complex may be bonded in a non-covalent manner (e.g., hydrogen bonds, ionic bonds, hydrophobic interactions, van der Waals forces, etc.). Thus, as used herein, the term "complex" refers to a molecule formed by binding multiple types of molecules such as polypeptides, polynucleotides, lipids, sugars, and small molecules by a method other than a covalent bond.
[0026] In the present disclosure, the term "functionally equivalent sequence" is used in relation to the peptides and the like of the present disclosure, and means an amino acid sequence or a nucleic acid sequence having a function equivalent to that of the original. Representative functionally equivalent sequences include, but are not limited to, sequences containing conservatively substituted amino acids.
[0027] In the present disclosure, "conservative substitution" refers to an amino acid substitution in which the hydrophilicity index or / and hydrophobicity index of the original amino acid and the substituted amino acid are similar as described above. Examples of conservative substitution are well known to those skilled in the art, and include, but are not limited to, the following substitutions within each group: arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and valine, leucine, and isoleucine. It is understood that a specific sequence of the tripeptide of the present disclosure can typically be partially or entirely conservatively substituted.
[0028] As used herein, "variants," "derivatives," "analogs," or "mutants" (of proteins, peptides, etc.) are used interchangeably and preferably, but without limitation, include molecules that contain regions of substantial homology to the protein or peptide of interest, and in the case of amino acid sequences, nucleic acid sequences (nucleotide sequences, base sequences), such sequences are referred to as "modified sequences," "derived sequences," "analogous sequences," or "mutant sequences." Such molecules, in various embodiments, are at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% identical over the same size of the amino acid sequence or when compared to sequences aligned by computer homology programs known in the art, or the nucleic acids encoding such molecules are hybridizable to sequences encoding the component proteins under (highly) stringent, moderately stringent, or non-stringent conditions. This refers to a protein that is a product of protein modification by amino acid substitution, deletion and addition, respectively, and the variant or derivative still exhibits the biological function of the original protein, although not necessarily to the same degree. The variant may have a sequence that is preferably 70% or more identical to the original sequence, more preferably 80% or more identical, even more preferably 90% or more identical, even more preferably 95% or more identical, 98% or more identical, 99% or more identical. For example, the biological function of such a protein can be examined by suitable and available in vitro assays described herein or known in the art. As used herein, "functionally active" refers to a polypeptide, i.e., a fragment or derivative, that has a structural function, a regulatory function, or a biochemical function of a protein, such as a biological activity, according to the embodiment to which the polypeptide, i.e., the fragment or derivative, of the present disclosure relates. Thus, in one embodiment, the variant of the present disclosure refers to a functional equivalent.
[0029] As used herein, the terms "protein", "polypeptide" and "peptide" are used interchangeably herein to refer to a polymer of amino acids of any length. As used herein, an amino acid polymer having a length of 3, 4, 5, 6, 7, 8, 9, or 10 amino acids is specifically referred to as an "oligopeptide". The length of an oligopeptide is preferably 3 to 10 amino acids, more preferably 3 to 6 amino acids, and even more preferably 3 to 5 amino acids. The polymer may be linear, branched, or cyclic. The amino acids may be natural or non-natural, or may be modified. The term may also include those assembled into a complex of multiple polypeptide chains. The term also includes naturally or artificially modified amino acid polymers. Such modifications include, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, methylation, trimethylation, or any other manipulation or modification (e.g., conjugation with a labeling component). This definition also includes, for example, polypeptides containing one or more analogs of amino acids (e.g., including unnatural amino acids, etc.), peptide-like compounds (e.g., peptoids), and other modifications known in the art. In this specification, "amino acid" is a general term for organic compounds having an amino group and a carboxyl group. When a polypeptide according to an embodiment of the present disclosure contains a "specific amino acid sequence", any amino acid in the amino acid sequence may be chemically modified. Any amino acid in the amino acid sequence may form a salt or a solvate. Any amino acid in the amino acid sequence may be L-type or D-type. Even in such cases, the protein according to an embodiment of the present disclosure can be said to contain the above-mentioned "specific amino acid sequence". Examples of chemical modifications that amino acids contained in proteins undergo in vivo include N-terminal modifications (e.g., acetylation, myristoylation, etc.), C-terminal modifications (e.g., amidation, glycosylphosphatidylinositol addition, etc.), and side chain modifications (e.g., phosphorylation, glycosylation, etc.). The amino acids may be natural or unnatural as long as they satisfy the purpose of the present disclosure.
[0030] In this specification, peptides capable of disrupting self-aggregation are sometimes referred to as "disrupting peptides," and peptides capable of separating bonds are referred to as "separating peptides." Without wishing to be bound by theory, it is understood that even if a peptide has separation ability, it is not capable of releasing adhesion.
[0031] As used herein, "polynucleotide", "oligonucleotide" and "nucleic acid" are used interchangeably to refer to a polymer of nucleotides of any length. This term also includes "oligonucleotide derivative" or "polynucleotide derivative". "Oligonucleotide derivative" or "polynucleotide derivative" refers to an oligonucleotide or polynucleotide that contains a derivative of nucleotides or has a bond between nucleotides that is different from the usual one, and are used interchangeably. Specific examples of such oligonucleotides include 2'-O-methyl-ribonucleotides, oligonucleotide derivatives in which the phosphodiester bond in an oligonucleotide has been converted to a phosphorothioate bond, oligonucleotide derivatives in which the phosphodiester bond in an oligonucleotide has been converted to an N3'-P5' phosphoramidate bond, oligonucleotide derivatives in which the ribose and phosphodiester bond in an oligonucleotide have been converted to a peptide nucleic acid bond, oligonucleotide derivatives in which the uracil in an oligonucleotide has been replaced with C-5 propynyl uracil, oligonucleotide derivatives in which the uracil in an oligonucleotide has been replaced with C-5 thiazole uracil, oligonucleotide derivatives in which the cytosine in an oligonucleotide has been replaced with C-5 propynyl cytosine, oligonucleotide derivatives in which the cytosine in an oligonucleotide has been replaced with phenoxazine-modified cytosine, oligonucleotide derivatives in which the ribose in DNA has been replaced with 2'-O-propyl ribose, and oligonucleotide derivatives in which the ribose in an oligonucleotide has been replaced with 2'-methoxyethoxy ribose. Unless otherwise indicated, a particular nucleic acid sequence is also intended to encompass conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated.Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260: 2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). As used herein, "nucleic acid" is also used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide. As used herein, "nucleotide" may be natural or non-natural.
[0032] As used herein, the term "gene" refers to a factor that determines a genetic trait, and may refer to a "polynucleotide," an "oligonucleotide," and a "nucleic acid."
[0033] In this specification, the "homology" of a gene refers to the degree of identity between two or more gene sequences, and generally, "homology" refers to a high degree of identity or similarity. Therefore, the higher the homology between two genes, the higher the identity or similarity between those sequences. Whether two types of genes have homology can be examined by direct comparison of the sequences, or in the case of nucleic acids, by hybridization methods under stringent conditions. When two gene sequences are directly compared, the genes have homology when the DNA sequences between the gene sequences are typically at least 50% identical, preferably at least 70% identical, and more preferably at least 80%, 90%, 95%, 96%, 97%, 98% or 99% identical. The concept of "homology" also applies to amino acid sequences, and in this case, the numerical value of identity can be interpreted as being replaced with the amino acid sequence. Thus, as used herein, a "homolog" or "homologous gene product" refers to a protein in another species, preferably a microorganism, more preferably a bacterium, that performs the same biological function as a protein component of a complex as further described herein. Such a homolog may also be referred to as an "orthologous gene product." It is understood that such homologs, homologous gene products, orthologous gene products, etc. may also be used as long as they are consistent with the purposes of the present disclosure.
[0034] Amino acids may be referred to herein by either their commonly known three-letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may also be referred to by their commonly accepted one-letter codes. In this specification, the comparison of similarity, identity, and homology of amino acid and base sequences is calculated using the sequence analysis tool BLAST with default parameters. Identity searches can be performed, for example, using NCBI's BLAST2.7.1 (published 2017.10.19). The value of "identity" in this specification usually refers to the value when aligned under default conditions using the above BLAST. However, if a higher value is obtained by changing the parameters, the highest value is taken as the identity value. If identity is evaluated in multiple regions, the highest value among them is taken as the identity value. "Similarity" is a value that takes into account similar amino acids in addition to identity.
[0035] In one embodiment of the present disclosure, "several" may be, for example, 10, 8, 6, 5, 4, 3, or 2, or any of these values or less. It is known that a polypeptide that has one or several amino acid residues deleted, added, inserted, or substituted with other amino acids maintains its biological activity (Mark et al., Proc Natl Acad Sci USA. 1984 Sep; 81(18): 5662-5666., Zoller et al., Nucleic Acids Res. 1982 Oct 25; 10(20): 6487-6500., Wang et al., Science. 1984 Jun 29; 224(4656): 1431-1433.). A polypeptide with deletions or the like can be prepared, for example, by site-directed mutagenesis or random mutagenesis. For example, KOD-Plus-Mutagenesis Kit (TOYOBO CO., LTD.) can be used for site-directed mutagenesis. A polypeptide having the same activity as the wild type can be selected from among mutant polypeptides into which deletions or the like have been introduced by performing various characterizations such as FACS analysis and ELISA.
[0036] In one embodiment of the present disclosure, the numerical value of identity, etc., "70% or more" may be, for example, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% or more, or may be within the range of any two of the starting numerical values. The above-mentioned "identity" is calculated by calculating the ratio of the number of homologous amino acids in two or more amino acid sequences according to a known method as described above. Specifically, before calculating the ratio, the amino acid sequences of the amino acid sequences to be compared are aligned, and gaps are introduced into a part of the amino acid sequence if necessary to maximize the ratio of identical amino acids. Methods for alignment, methods for calculating the ratio, methods for comparison, and computer programs related thereto are conventionally well known in the art (for example, BLAST, etc., as described above). In this specification, "identity" and "similarity" can be expressed as values measured by BLAST of NCBI, unless otherwise specified. When comparing amino acid sequences with BLAST, the algorithm Blastp can be used with the default settings. The measurement results are expressed as numbers as Positives or Identities.
[0037] As used herein, the term "polynucleotide that hybridizes under stringent conditions" refers to well-known conditions commonly used in the art. Such polynucleotides can be obtained by colony hybridization, plaque hybridization, Southern blot hybridization, or the like, using a polynucleotide selected from the polynucleotides disclosed herein as a probe. Specifically, the term refers to a polynucleotide that can be identified by hybridizing a filter on which DNA derived from colonies or plaques is immobilized in the presence of 0.7 to 1.0 M NaCl at 65°C, and then washing the filter at 65°C using a 0.1 to 2-fold concentration of SSC (saline-sodium citrate) solution (the composition of a 1-fold concentration SSC solution is 150 mM sodium chloride and 15 mM sodium citrate). For example, the following conditions can be adopted as the "stringent conditions." (1) using low ionic strength and high temperature for washing (e.g., 0.015 M sodium chloride / 0.0015 M sodium citrate / 0.1% sodium dodecyl sulfate at 50°C), (2) using a denaturing agent such as formamide during hybridization (e.g., 50% (v / v) formamide with 0.1% bovine serum albumin / 0.1% Ficoll / 0.1% polyvinylpyrrolidone / 50 mM sodium phosphate buffer pH 6.5, with 750 mM sodium chloride, 75 mM sodium citrate at 42°C), or (3) incubating overnight at 37°C in a solution containing 20% formamide, 5x SSC, 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 mg / ml denatured sheared salmon sperm DNA, followed by washing the filters with 1x SSC at approximately 37-50°C. The formamide concentration may be 50% or more, and the washing time may be 5, 15, 30, 60, or 120 minutes or more.Factors that affect the stringency of the hybridization reaction include temperature, salt concentration, and more. For details, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995). Examples of "highly stringent conditions" are 0.0015M sodium chloride, 0.0015M sodium citrate, 65-68°C, or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide, 42°C. Hybridization can be performed according to the method described in experimental books such as Molecular Cloning 2nd ed., Current Protocols in Molecular Biology, Supplement 1-38, DNA Cloning 1: Core Techniques, A Practical Approach, Second Edition, Oxford University Press (1995). Here, sequences that hybridize under stringent conditions preferably exclude sequences that contain only A or T sequences. Moderately stringent conditions can be readily determined by one of skill in the art based on, for example, the length of the DNA, and are set forth in Sambrook et al., Molecular Cloning: A Laboratory Manual, No. 3, Vol. 1, 7.42-7.45 Cold Spring Harbor Laboratory Press, 2001, and include the use of, for nitrocellulose filters, a pre-wash solution of 5xSSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization conditions of about 50% formamide, 2xSSC-6xSSC (or other similar hybridization solutions, such as Stark's solution in about 50% formamide at about 42°C) at about 40-50°C, and wash conditions of 0.5xSSC, 0.1% SDS at about 60°C.Thus, a polypeptide as used in this disclosure also includes a polypeptide encoded by a nucleic acid molecule that hybridizes under high or moderate stringency conditions to a nucleic acid molecule encoding a polypeptide specifically described in this disclosure.
[0038] The peptides of the present disclosure may preferably be "purified" or "isolated". As used herein, a "purified" substance or biological factor (e.g., nucleic acid or protein, etc.) refers to a substance or biological factor from which at least a portion of naturally associated factors have been removed. Thus, the purity of the biological factor in a purified biological factor is usually higher (i.e., concentrated) than the state in which the biological factor is normally present. As used herein, the term "purified" means that the same type of biological factor is present in an amount of preferably at least 75% by weight, more preferably at least 85% by weight, even more preferably at least 95% by weight, and most preferably at least 98% by weight. The substance or biological factor used in the present disclosure is preferably a "purified" substance. As used herein, an "isolated" substance or biological factor (e.g., nucleic acid or protein, etc.) refers to a substance or biological factor from which naturally associated factors have been substantially removed. The term "isolated" as used herein does not necessarily denote purity, as this can vary depending on the purpose, but, if necessary, preferably means that at least 75% by weight, more preferably at least 85% by weight, even more preferably at least 95% by weight, and most preferably at least 98% by weight of the same type of biological factor is present. The materials used in this disclosure are preferably "isolated" materials or biological factors.
[0039] As used herein, the terms "fragment" and "fragment" are used interchangeably herein and refer to a polypeptide or polynucleotide having a sequence length of 1 to n-1 relative to a full-length polypeptide or polynucleotide (length is n). The length of the fragment can be appropriately changed depending on the purpose, and for example, the lower limit of the length can be 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, or more amino acids in the case of a polypeptide, and lengths represented by integers not specifically listed here (e.g., 11, etc.) can also be suitable as the lower limit. In addition, in the case of a polynucleotide, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, or more nucleotides can also be used, and lengths represented by integers not specifically listed here (e.g., 11, etc.) can also be suitable as the lower limit. In the present specification, such fragments are understood to be within the scope of the present disclosure, for example, when the full-length one functions as a separation active molecule, as long as the fragment itself also has a function as a peptide.
[0040] As used herein, the term "biological function" refers to a specific function that a gene, a nucleic acid molecule, or a polypeptide related thereto may have in vivo or in vitro, including, but not limited to, a disintegration function, a separation function, and the like. As used herein, a biological function may be exerted by a corresponding "biological activity." As used herein, "biological activity" refers to an activity that a certain factor (e.g., a polynucleotide, a protein, etc.) may have, and includes activities that exert various functions (e.g., a disintegration function, a separation function). A "biological activity" may be an activity exerted in vivo, or an activity exerted in vitro by secretion, etc. For example, when a certain factor is an enzyme, its biological activity includes its enzymatic activity. Such biological activity can be measured by techniques well known in the art. Thus, "activity" refers to various measurable indicators that indicate or reveal binding (either directly or indirectly); affect a response (i.e., have a measurable effect in response to some exposure or stimulus); and can also include, for example, the affinity of a compound to bind directly to a polypeptide or polynucleotide of the present disclosure, or, for example, a measure of the amount of an upstream or downstream protein or other similar function after some stimulus or event.
[0041] As used herein, the term "expression" of a gene, polynucleotide, polypeptide, etc. refers to the gene, etc. undergoing a certain action in vivo to become a different form. Preferably, the term refers to the gene, polynucleotide, etc. being transcribed and translated to become a polypeptide, but transcription to produce an mRNA is also an aspect of expression. Thus, as used herein, the term "expression product" includes such a polypeptide or protein, or mRNA. More preferably, such a polypeptide form may be one that has undergone post-translational processing. For example, the expression level of a peptide can be determined by any method. Specifically, the expression level of a peptide can be known by evaluating the amount of mRNA encoding the peptide, the amount of the peptide, and the biological activity of the peptide. The amount of mRNA, polypeptide, or protein encoding the peptide can be determined by methods detailed elsewhere in this specification or other methods known in the art.
[0042] As used herein, "analogy," "functional equivalent," or "functional equivalent" refers to any entity that has the same intended function but a different structure compared to the original entity of interest. Thus, it is understood that the functional equivalent of the peptide of the present disclosure is not the peptide itself, but a mutant or variant (e.g., an amino acid sequence variant, etc.) thereof that has the biochemical action of the peptide, such as the function of separating bonds or disrupting self-aggregation, and that can be changed into a mutant or variant having the biochemical action of the peptide at the time of acting (e.g., including a nucleic acid encoding the mutant or variant, and a vector, cell, etc. containing the nucleic acid). In the present disclosure, it is understood that the functional equivalent of a peptide can be used in the same way as the original peptide, even if not specifically mentioned. Functional equivalents can be found by searching a database, etc. As used herein, "search" refers to using a certain nucleic acid sequence to find other nucleic acid sequences having a specific function and / or property, electronically, biologically, or by other methods. Examples of electronic searches include, but are not limited to, BLAST (Altschul et al., J. Mol. Biol. 215: 403-410 (1990)), FASTA (Pearson & Lipman, Proc. Natl. Acad. Sci., USA 85: 2444-2448 (1988)), Smith and Waterman method (Smith and Waterman, J. Mol. Biol. 147: 195-197 (1981)), and Needleman and Wunsch method (Needleman and Wunsch, J. Mol. Biol. 48: 443-453 (1970)). Examples of biological searches include, but are not limited to, stringent hybridization, microarrays in which genomic DNA is attached to a nylon membrane or the like or to a glass plate (microarray assay), PCR, and in situ hybridization.As used herein, it is intended that the gene used in the present disclosure should also include corresponding genes identified by such electronic and biological searches.
[0043] As a functional equivalent of the present disclosure (polypeptide, etc.), an amino acid sequence in which one or more amino acids have been inserted, substituted or deleted, or added to one or both termini thereof can be used. In the present specification, "an amino acid sequence in which one or more amino acids have been inserted, substituted or deleted, or added to one or both termini thereof" means that the amino acid sequence has been modified by a well-known technical method such as site-directed mutagenesis, or by natural mutation, by substitution of a number of amino acids to the extent that would occur naturally. The modified amino acid sequence may be, for example, one in which 1 to 30, preferably 1 to 20, more preferably 1 to 9, even more preferably 1 to 5, and particularly preferably 1 to 2 amino acids have been added to one or both termini thereof. The modified amino acid sequence may preferably be an amino acid sequence having one or more (preferably one or several, or 1, 2, or 3) conservative substitutions in the amino acid sequence of AVL, ATL, or SVL. Here, "conservative substitution" means replacing one or more amino acid residues with other chemically similar amino acid residues so as not to substantially alter the function of the peptide. For example, a hydrophobic residue may be replaced with another hydrophobic residue, a polar residue may be replaced with another polar residue having the same charge, and the like. Functionally similar amino acids that can be used for such substitutions are known in the art for each amino acid. Specific examples of non-polar (hydrophobic) amino acids include alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine, methionine, and the like. Polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, cysteine, and the like. Positively charged (basic) amino acids include arginine, histidine, lysine, and the like. In addition, negatively charged (acidic) amino acids include aspartic acid, glutamic acid, and the like.
[0044] As used herein, the term "support" refers to a substance capable of carrying polypeptides, proteins, polynucleotides, cells, bacteria, or viruses. Any substance capable of forming a solid surface can be used as a material for use as a support, and includes, but is not limited to, lipid bilayers (e.g., liposomes), glass, silica, silicon, ceramics, silicon dioxide, plastics, metals (including alloys), titanium, acrylic, natural and synthetic polymers (e.g., polystyrene, polypropylene, polyethylene, polyvinyl chloride, polyurethane, cellulose, chitosan, dextran, nylon, polycarbonate, polylactic acid, and polytetrafluoroethylene (PTFE)).
[0045] As used herein, the term "kit" refers to a unit in which the parts to be provided (e.g., enzymes, buffer solutions, instructions, etc.) are provided, usually separated into two or more compartments. This kit form is preferred when the purpose is to provide a composition that should not be provided in a mixed state for reasons of stability, etc., but is preferably mixed immediately before use. Such a kit is advantageously provided with instructions or instructions, preferably describing how to use the parts to be provided (e.g., peptides), or how to dispose of the reagents or waste liquid after use. When the kit is used as a reagent kit in this specification, the kit usually includes instructions describing how to use the enzymes, etc.
[0046] In this specification, the term "instructions" refers to instructions for a user on how to use the present disclosure. The instructions contain text instructing how to use the present disclosure. If necessary, the instructions are prepared in accordance with a format specified by the supervisory agency of the country in which the present disclosure is implemented (e.g., the Ministry of Health, Labor and Welfare or the Ministry of Agriculture, Forestry and Fisheries in Japan, the Food and Drug Administration (FDA), the Department of Agriculture (USDA), etc. in the United States), and it is clearly stated that the instructions have been approved by the supervisory agency. The instructions may be provided in paper form, but are not limited thereto, and may also be provided in the form of, for example, electronic media (e.g., a homepage provided on the Internet, e-mail).
[0047] (Preferred embodiment) Preferred embodiments of the present disclosure are described below. The embodiments provided below are provided for a better understanding of the present disclosure, and it is understood that the scope of the present disclosure should not be limited to the following description. Therefore, it is clear that a person skilled in the art can make appropriate modifications within the scope of the present disclosure in light of the description in this specification. It is also understood that the following embodiments can be used alone or in combination.
[0048] (Peptides with disruptive or detaching functions) In one aspect, the present disclosure provides a peptide comprising the amino acid sequence AVL, SVL or ATL or a modified sequence thereof (particularly, a functionally equivalent sequence). Here, it is understood that the "functionally equivalent sequence" includes any peptide having the ability of AVL, SVL or ATL peptide to disrupt the self-aggregation of AtaA, or the ability to separate the binding of AtaA fragments to other targets (e.g., functionalizing molecules such as streptavidin and neutral avidin). Preferably, the peptide of the present disclosure comprises the amino acid sequence of AVL, SVL or ATL. More preferably, the peptide of the present disclosure consists of the amino acid sequence of AVL, SVL or ATL.
[0049] The peptide of the present disclosure may be in the form of an oligopeptide containing the amino acid sequence of AVL, SVL, or ATL or a modified sequence thereof. The oligopeptide may have 1, 2, 3, 4, 5, 6, 7 or more amino acids added to the N-terminus, C-terminus, or both of the amino acid sequence of AVL, SVL, or ATL or a modified sequence thereof. Preferably, the amino acid added to the N-terminus, C-terminus, or both is an amino acid with a short side chain (e.g., Gly, Ala, Val, Leu, Ile, etc.) or an amino acid with no charge in the side chain (amino acid other than Glu, Asp, Lys, His, Arg).
[0050] In a preferred embodiment, the peptide consists of the amino acid sequence AVL, SVL or ATL or a functional equivalent thereof. In such a preferred embodiment, a short peptide, a tripeptide, surprisingly exhibits the ability to disrupt the binding of AtaA to other molecules, such as streptavidin and neutral avidin.
[0051] In one aspect, the present disclosure provides a composition for separating the binding of AtaA or its variant with other molecules.The composition contains a peptide comprising amino acid sequence AVL, SVL or ATL or its functional equivalent sequence.Preferably, the peptide of the present disclosure comprises amino acid sequence AVL, SVL or ATL.More preferably, the peptide contained in the composition is AVL, SVL or ATL tripeptide.
[0052] In a preferred embodiment, the AtaA or its variant or fragment thereof that is the subject of the peptide of the present disclosure to disrupt self-aggregation or separate binding may be any embodiment of the "AtaA polypeptide" described herein. In one embodiment, the peptide of the present disclosure is used to disrupt aggregates of AtaA or its variant. Disruption of the aggregates facilitates isolation, purification, etc. of AtaA or its variant. The peptide of the present disclosure is also used to disrupt aggregation of cells expressing a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 4 or a modified sequence thereof or a fragment thereof. Thus, the peptide of the present disclosure can disrupt microbial aggregates and biofilms formed by AtaA or its variant. In another embodiment, the peptide of the present disclosure is used to separate binding between the AtaA fragment shown in SEQ ID NO: 1 or its variant and another target.
[0053] In one embodiment, the present disclosure provides a method for attaching and detaching a microorganism, comprising: (1) contacting a microorganism to which nonspecific adhesion has been imparted or enhanced by the introduction of an autotransporter adhesin derived from an Acinetobacter microorganism, for example, a DNA encoding the amino acid sequence shown in SEQ ID NO: 4 or a modified sequence thereof, or a fragment thereof, with a carrier, thereby attaching the microorganism to the carrier; and (2) washing the carrier to which the microorganism is attached in the presence of a peptide of the present disclosure (for example, a peptide described in item (1) or (2) of the present disclosure), thereby detaching the microorganism from the carrier. For the attachment and detachment method, for example, a technique described in JP 2017-55676 A can be used. In this specification, the term "attachment and detachment (method)" refers to a method including a step (operation) of attaching a microorganism to a carrier and a step (operation) of detaching the microorganism attached to the carrier.
[0054] In the above step (1), i.e., the adhesion step, a microorganism (herein also referred to as "adhesion-conferring microorganism") having non-specific adhesion conferred or enhanced by the introduction of DNA encoding AtaA derived from an Acinetobacter microorganism (for example, a sequence encoding the amino acid sequence shown in SEQ ID NO: 4 or a modified sequence thereof, or a fragment thereof; also referred to as "adhesion-conferring DNA" herein) is prepared. The adhesion-conferring DNA is preferably isolated and identified from Acinetobacter sp. Tol5 strain, and may be any AtaA polypeptide described in detail elsewhere herein, including a sequence encoding the amino acid sequence shown in SEQ ID NO: 4 or a modified sequence thereof, or a fragment thereof.
[0055] Various microorganisms can be used as the microorganisms (target microorganisms) into which the adhesiveness-imparting DNA is introduced. The target microorganisms are not particularly limited, but include, for example, microorganisms that have no or weak nonspecific adhesiveness. The target microorganisms may be any of wild-type strains, mutant strains, and genetically modified strains. Appropriate microorganisms are selected depending on the application of the present invention.Examples of microorganisms that can be used as target microorganisms include bacteria of the genus Escherichia, such as Escherichia coli, bacteria of the genus Acinetobacter, such as Acinetobacter calcoaceticus, bacteria of the genus Ralstonia, such as Ralstonia eutropha, bacteria of the genus Pseudomonas, such as Pseudomonas putida and Pseudomonas fluorescens, bacteria of the genus Aeromonas, such as Aeromonas caviae, bacteria of the genus Alcaligenes, such as Alcaligenes latus, and bacteria of the genus Escherichia. latus, Xanthomonas bacteria such as Xanthomonas campestris, Desulfomonile bacteria such as Desulfomonile tiedjei, Desulfuromonas bacteria such as Desulfuromonas chloroethenica, Chromobacterium bacteria such as Chromobacterium chocolatum, Burkholderia bacteria such as Burkholderia arboris, Rhodobacter bacteria, Acidovorax bacteria such as Acidovorax facilis. facilis and Zymomonas bacteria, such as Zymomonas mobilis. By introducing the adhesion-imparting DNA into a target microorganism and transforming it, a microorganism with nonspecific adhesion imparted or enhanced can be obtained.Typically, the adhesiveness-imparting DNA is ligated to an appropriate vector, and a target microorganism (host microorganism) is transformed with the vector to obtain a microorganism with imparted or enhanced nonspecific adhesiveness. Specifically, the vector is prepared by ligating the DNA under the control of a constitutively expressed promoter or under the control of an inducible expression promoter. A microorganism with imparted or enhanced nonspecific adhesiveness can be obtained by transforming a host microorganism with the vector.
[0056] In step (1), the prepared microorganisms with adhesive properties are brought into contact with the carrier. The contact here is performed under conditions that allow the microorganisms with adhesive properties to adhere to the carrier. The microorganisms with adhesive properties have high adhesive power and exhibit adhesive properties to various carriers under normal culture conditions. Therefore, except for special cases (typically, when the detachment treatment liquid used in step (2) described below is used as the medium or under low ionic strength (see WO 2014 / 156736)), they adhere to the carrier by contact.
[0057] The adherent microorganisms attached to the carrier in step (1) are usually subjected to one or more treatments or reactions (for details of the treatments or reactions, see, for example, JP 2017-55676 A). In the present disclosure, step (2), i.e., a detachment step, is then carried out. In step (2), the adherent microorganisms attached to the carrier are treated with a solution containing the isolated peptide of the present disclosure that satisfies certain conditions, and the adherent microorganisms can be detached from the carrier.
[0058] In one embodiment, the other molecule is streptavidin, neutral avidin, or a variant thereof. In various test systems using streptavidin, neutral avidin, or a variant thereof, separation and binding can be freely controlled, which is useful.
[0059] In one representative embodiment, the disclosure provides compositions for disrupting self-aggregation of a polypeptide having the amino acid sequence set forth in SEQ ID NO:4, or modified sequences and fragments thereof that have self-aggregating properties.
[0060] In one embodiment, the other molecule is a functionalizing entity. Examples of functionalizing entities include, but are not limited to, those having functions useful for biosensors, separation and labeling of biomolecules, regenerative medicine, production of bio-organic-inorganic hybrid materials, surface modification and functionalization, fermentation industry, pharmaceutical industry, chemical industry, and the like. In a particular embodiment, the functionalizing entity is a protein and / or a peptide. In a more specific embodiment, the functionalizing entity is streptavidin, neutral avidin, derivatives thereof, enzymes, antibodies, fluorescent molecules, receptors, functional peptides (antibacterial, fluorescent, signaling factors, inducers, etc.), nucleic acid aptamers, serum components, etc., or cells. In a particular embodiment, the peptide of the present disclosure is provided as a complex or fusion with the functional molecule.
[0061] (AtaA polypeptide) The peptides of the present disclosure are useful for disrupting the self-aggregation of a full-length AtaA polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4, or polypeptides having modified sequences and fragments thereof that have self-aggregating properties.
[0062] The peptides of the present disclosure are also useful for disrupting aggregation in cells expressing a full-length AtaA polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 4, or a polypeptide comprising a modified sequence or fragment thereof that has self-aggregation properties. Cells expressing the AtaA polypeptide or a modified sequence or fragment thereof may be not only cells that naturally express AtaA, such as Acinetobacter sp. Tol5 strain, but also bacterial cells in which the AtaA polypeptide is expressed by means of a vector or the like.
[0063] (Protein or peptide production) The proteins and peptides of the present disclosure can be produced by microbial expression systems or by chemical synthesis.
[0064] Of course, short peptides such as tripeptides can be synthesized by peptide synthesis methods well known in the art.
[0065] (Use of peptides) In one aspect, the peptide of the present disclosure is useful in material engineering processes. In another aspect, the disrupting peptide and the isolated peptide of the present disclosure are useful in industries using bioprocesses. In an embodiment, the disrupting peptide and the isolated peptide of the present disclosure disrupt the self-aggregation of the AtaA polypeptide and immobilize proteins, peptides, or microorganisms in a densely packed manner, thereby enabling efficient implementation of material engineering processes such as surface modification and material design, and bioprocesses in technical fields such as fermentation industry, pharmaceutical industry, chemical industry, regenerative medicine, cell engineering, medical engineering, and biosensors. In addition, the peptide of the present disclosure can separate cells (including microorganisms and biofilms) expressing the AtaA polypeptide that are immobilized on a support from the support, allowing the cells or carriers to be reused by adjusting the thickness of the biofilm in the biofilm reactor or by separating the cells from the adherent or immobilized state.
[0066] (Production of AtaA polypeptide) In one embodiment, the adhesive polypeptide and fusion polypeptide of the present disclosure are produced by an expression system using a microorganism. The adhesive polypeptide or fusion polypeptide of the present disclosure can be produced as a recombinant protein in E. coli by a method commonly used in laboratories. That is, a gene encoding an AtaA fragment or a fusion peptide obtained by fusing the fragment with a peptide is inserted into an appropriate position of an appropriate E. coli expression vector such as the pET system, E. coli is transformed, and gene expression is induced by adding an inducer or is constitutively expressed by a constitutive expression promoter. The protein is often produced in the cytoplasm, but it can also be secreted and produced in the periplasm. In the latter case, the signal peptide inherent to the AtaA protein or a gene sequence encoding a signal peptide incorporated in an E. coli expression vector is connected to the 5'-end side of the protein coding for the protein, so that the protein is produced in a form in which the signal peptide is added to the amino-terminal side of the protein. Note that the signal peptide is cleaved and removed when the produced protein is secreted into the periplasm, so that the resulting AtaA fragment or its fusion protein does not contain a signal peptide. The protein produced in the cells is usually separated and purified from the soluble components, but it may be separated from the inclusion body and then refolded to obtain an active protein. The produced protein can be separated and purified by a commonly used affinity purification method using a His tag or a strepto tag fused to the protein in advance. Furthermore, when a SNAP tag or the like is fused, it may be separated and purified using a molecule having a benzylguanyl group. To further increase the degree of purification, ion exchange chromatography or gel filtration may be used in combination. In this method for producing an adhesive polypeptide using a microorganism, detailed conditions such as a method for expressing the adhesive polypeptide, a host for expressing the adhesive polypeptide, and a method for purifying the adhesive polypeptide secreted from the host can be appropriately adjusted by a person skilled in the art. Furthermore, the adhesive polypeptide of the present disclosure can be expressed using various expression systems such as a secretory production system and a cell-free expression system in addition to the intracellular expression system of a microorganism.
[0067] The methods for causing the above-mentioned microorganisms to produce a desired polypeptide, including the adhesive polypeptide of the present disclosure, are merely exemplary, and a person skilled in the art can easily design and construct a DNA fragment to be inserted into an expression vector by creating a synthetic gene using techniques commonly used in the technical field and referring to the nucleic acid sequence (base sequence) or amino acid sequence of the gene of the present disclosure.
[0068] (General technology) The molecular biological techniques, biochemical techniques, and microbiological techniques used in this specification are well known and commonly used in the art, and are described, for example, in Sambrook J. et al. (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor and its 4th Ed. (2012), Okada Masato and Miyazaki Kaori, 2011, Protein Experimental Notes, Revised 4th Edition, Vol. 1 and 2, Yodosha, and the like, the relevant parts of which (which may be in their entirety) are incorporated by reference in this specification.
[0069] (Note) In this specification, "or" is used when "at least one or more" of the items listed in the sentence can be employed. The same applies to "alternative." In this specification, when it is specified that "within a range of two values," the range includes the two values themselves.
[0070] All references cited herein, including scientific literature, patents, patent applications, and the like, are hereby incorporated by reference in their entirety to the same extent as if each was specifically set forth.
[0071] The present disclosure has been described above by showing preferred embodiments for ease of understanding. The present disclosure will be described below based on examples, but the above description and the following examples are provided for illustrative purposes only and are not provided for the purpose of limiting the present disclosure. Therefore, the scope of the present disclosure is not limited to the embodiments or examples specifically described in this specification, but is limited only by the scope of the claims. EXAMPLES
[0072] Examples are described below. The handling of organisms used in the following examples complied with the standards stipulated by Nagoya University, regulatory authorities, and the Cartagena Protocol, when necessary. The specific reagents used were the products described in the examples, but equivalent products from other manufacturers (Sigma-Aldrich, Fujifilm Wako Pure Chemical Industries, Nacalai Tesque, R&D Systems, USCN Life Science INC, Thermo Fisher Scientific, Kanto Chemical, Funakoshi, Tokyo Kasei, Merck, etc.) can also be used.
[0073] The Nhead recombinant protein used in the following examples was produced as follows. (Production example) The construct design of the Nhead recombinant protein is shown in SEQ ID NO:5. The Nhead recombinant protein designed in this way expresses a recombinant polypeptide corresponding to the amino acid fragment of positions 59 to 325 of the AtaA sequence: the amino acid fragment of positions 2 to 268 of SEQ ID NO:1. To prepare this construct, a gene fragment encoding amino acids 1 to 268 of SEQ ID NO:1 was inserted into the restriction enzyme XbaI / BsaI digested fragment of the pIBA-GCN4tri-His vector, and the pIBA::Nhead recombinant DNA (pIBA-GCN4tri-His::ataA 59-325 ) was prepared. BL21 star(DE3;pIBA-GCN4tri-His::ataA 59-325An overnight culture of ) was diluted 1:100 in LB medium and incubated at 37°C for 3 h. After incubation, 0.2 μg / ml anhydrotetracycline (AHTC) was added to the medium and further incubated at 28°C for 6 h. Cells were harvested by centrifugation at 5,000×g for 15 min at 4°C, resuspended in lysis buffer (20 mM Tris-HCl, 150 mM NaCl and 20 mM imidazole, pH 9.0) and lysed at 1,000 bar for 10 min using a high-pressure homogenizer (LAB 2000, SMT Co., Ltd.). After centrifugation at 10,000×g for 15 min at 4°C, the supernatant was loaded onto a Ni-NTA Superflow column (Qiagen NV) and unbound proteins were removed by washing twice with lysis buffer. The bound protein was eluted with elution buffer (20 mM Tris-HCl, 150 mM NaCl, and 400 mM imidazole, pH 9.0). The eluted protein was loaded onto an anion exchange column (HiTrap Q HP, GE Healthcare), and the flow-through fraction containing the recombinant protein was dialyzed against 50 mM phosphate buffer (pH 6.0). The recombinant protein was then purified using a cation exchange column (HiTrap SP HP, GE Healthcare) with a linear concentration gradient of 0 to 1,000 mM NaCl in phosphate buffer (pH 6.0). The peak fraction containing the recombinant protein was concentrated by ultrafiltration using a centrifugal filter device (Amicon ultra, EMD Millipore) and loaded onto a gel filtration column (HiLoad 26 / 60 Superdex 200pg, GE Healthcare) equilibrated with 25 mM Tris-HCl (pH 9.0) for gel filtration purification. The product prepared by the above procedure was used in the following examples.
[0074] Example 1: Characteristics of aggregates of Acinetobacter sp. Tol5 strain In this example, aggregates of Acinetobacter sp. Tol5 strain were observed under a microscope.
[0075] (method) (Preparation of flow cell) The basic structure of the flow cell system constructed in this disclosure is a silicone tube for delivering cell suspension or fluid, and a glass tube for observing cells. To construct a rectangular flow cell system, silicone tubes with a length of 300 mm, an inner diameter of 1 mm, and an outer diameter of 2 mm were connected to both ends of a rectangular glass tube (Vitrocom) with a length of 50 mm and each inner diameter of 1 mm, and the connection was sealed with paraffin film. The inlet silicone tube was connected to a syringe pump (Legato 200, KD Scientific) via a three-way stopcock (Terumo Corporation), and fluid was delivered to the cell observation part (flow cell) of the rectangular glass tube.
[0076] A suspension of Acinetobacter sp. Tol5 cells suspended in BS-N medium was passed through the flow cell at a rate of 64 μl / min for 30 minutes to allow the Tol5 cell aggregates to adhere to the glass flow cell. Then, BS-N medium containing 0.1 mM AVL peptide, 0.1 mM ATL peptide, or 0.1 mM SVL peptide was passed through the flow cell at the same rate, and the behavior of the attached Tol5 cell aggregates was continuously observed with a digital microscope (Keyence VHX-200). As a control, BS-N medium not containing the peptide was passed through the flow cell at the same rate. The composition of the BS-N medium used in Example 1 is described in a paper (S. Ishii, J. Koki, H. Unno, K. Hori; Two Morphological Types of Cell Appendages on a Strongly Adhesive Bacterium, Acinetobacter sp. Strain Tol5, Appl. Environ. Microbiol. 70, (2004) 5026-5029) and a paper (H. Watanabe, Y. Tanji, H. Unno, K. Hori; Rapid Conversion of Toluene by an Acinetobacter sp. Tol5 Mutant Showing Monolayer Adsorption to Water-Oil Interface, J. Biosci. Bioeng. 106 (2008) 226-230).
[0077] (Results and Discussion) The results are shown in Figure 1. When the control medium not containing peptide was poured, there was no change in the bacterial cell aggregates of Acinetobacter sp. Tol5 strain, whereas when the AVL peptide, ATL peptide, or SVL peptide was added, the bacterial cell aggregates of Acinetobacter sp. Tol5 strain were rapidly disintegrated (within 10 seconds). This confirmed that the AVL peptide, ATL peptide, or SVL peptide is a factor that disrupts self-aggregation between AtaA proteins.
[0078] Example 2: Separation activity of AVL, ATL and SVL peptides In this example, we show that the binding between E. coli recombinant Nhead and streptavidin is separated by the AVL, ATL and SVL peptides.
[0079] (method) E. coli recombinant Nhead (fragment of AtaA polypeptide) was prepared according to the method described in (Production Example). Equal amounts of 0.2 mg / ml Nhead recombinant protein (SEQ ID NO: 5) and 0.2 mg / ml streptavidin were mixed and left to stand for 5 minutes. 40 μL of the above mixture was placed in a quartz cell, and the particle shape was measured using a DLS measurement device (Zetasizer Nano ZSP, Malvern Instruments, UK) equipped with a He-Ne laser (wavelength 633 nm), and it was confirmed that the Nhead recombinant protein and streptavidin were bound to form a complex. Then, AVL peptide was added to the mixture to a concentration of 0.2 μg / ml, mixed, left to stand for 5 minutes, and DLS measurement was performed again. DLS measurement was performed under the conditions of temperature 25 ° C, equilibration time 120 seconds, and scattering angle 173 °.
[0080] (Results and Discussion) The results are shown in Figures 2A to 2C. The complex between Nhead and streptavidin showed a diameter peak at a particle diameter of about 1000 nm, whereas when AVL peptide (Figure 2A), ATL peptide (Figure 2B) and SVL peptide (Figure 2C) were added to the complex between Nhead and streptavidin, a diameter peak was observed at a particle diameter of about 5 to 10 nm. From these results, it was considered that the addition of AVL peptide, ATL peptide and SVL peptide separated the binding between Nhead and streptavidin.
[0081] (Example 3: Repeated attachment / detachment procedures of biotinylated molecules) In this example, we demonstrate the reversible immobilization of biotinylated molecules using the bond between Nhead and streptavidin.
[0082] (method) Three types of solutions were prepared by dissolving Escherichia coli recombinant Nhead protein, streptavidin, and a biotinylated fluorescent peptide (the N-terminus of the peptide GGSGGSK (sequence number 6) modified with fluorescein and the C-terminus with biotin) in PBS buffer at 1 μM. First, 100 μl of PBS buffer was applied to a black 96-well polystyrene plate for fluorescence measurement. Then, the following operation (1) was performed to measure the negative control value (blank fluorescence value due to streptavidin adsorbed to the plate) before immobilizing the Nhead protein. Next, 100 μl of Nhead protein solution was applied. The plate was allowed to stand at 37° C. for 1 hour to allow the Nhead protein to adhere to the plate. Then, the following operations were repeated in the order of (1) → (2) → (1) → (2) → (1). (1) Streptavidin binding procedure (1-1) The solution was removed, and 100 μl of streptavidin solution was applied. (1-2) The plate was incubated at 28° C. for 30 minutes to allow streptavidin to bind to the Nhead protein immobilized on the plate. (1-3) The solution was removed, and 100 μl of biotinylated fluorescent peptide was applied. (1-4) The biotinylated fluorescent peptide was allowed to bind to streptavidin by leaving the plate at 28°C for 30 minutes. (1-5) Wash five times with 200 μl of PBS buffer. (1-6) 100 μl of PBS buffer was applied, and fluorescence measurement (excitation wavelength: 485 nm, fluorescence wavelength: 535 nm) was performed using a plate reader (PerkinElmer ARVO X3). (1-7) The buffer solution was removed. (2) Streptavidin separation procedure (2-1) The plate was washed twice with 200 μl of 100 μM AVL peptide solution and once with 200 μl of PBS buffer (applied and then removed). (2-2) 100 μl of PBS buffer was applied and the fluorescence value was measured again using a plate reader to determine the remaining fluorescence.
[0083] (Results and Discussion) The results are shown in Figure 3. In the fluorescence measurement performed after the first binding reaction of the biotinylated fluorescent peptide, an increase in the fluorescence value was observed. This result indicates that the biotinylated fluorescent peptide was bound to the complex of Nhead and streptavidin attached to the polystyrene plate. In the fluorescence measurement performed after the addition of the AVL peptide, a decrease in the fluorescence value was observed, indicating that the binding between Nhead and streptavidin was separated. Similar results were observed after the second binding reaction and separation reaction, and after the third binding reaction, indicating that the binding between Nhead and streptavidin was reversibly bound and separated.
[0084] (Notes) As described above, the present disclosure has been illustrated using preferred embodiments of the present disclosure, but the above description and examples are provided for illustrative purposes only and are not provided for the purpose of limiting the present disclosure. Therefore, it is understood that the present invention is not limited to the embodiments or examples specifically described in this specification, and its scope should be interpreted only by the claims. It is understood that the patents, patent applications and literature cited in this specification should be incorporated by reference to this specification in the same manner as if the contents themselves were specifically described in this specification. This application claims priority to Japanese Patent Application No. 2019-132490 filed on July 18, 2019 at the Japan Patent Office, the contents of which are incorporated by reference in their entirety in this application. [Industrial Applicability]
[0085] The present disclosure has utility in industries that use bioprocessing. [Sequence List Free Text]
[0086] SEQ ID NO: 1: Amino acid sequence of the AtaA fragment excluding the signal peptide and including methionine at the start SEQ ID NO:2: Nucleic acid sequence of the AtaA fragment excluding the signal peptide and including methionine at the start SEQ ID NO:3: Full length nucleic acid sequence of AtaA SEQ ID NO: 4: Full-length amino acid sequence of AtaA SEQ ID NO: 5: Amino acid sequence of the recombinant protein of the Nhead domain of AtaA SEQ ID NO: 6: Amino acid sequence of the artificial peptide
Claims
1. (1) An amino acid sequence as set forth in SEQ ID NO: 4, or (2) A modified sequence or fragment having self-aggregation properties, comprising a sequence having at least 90% sequence identity to positions 59 to 325 of SEQ ID NO:
4.
23. A composition comprising a peptide comprising or consisting of the amino acid sequence AVL, SVL or ATL for disrupting the self-aggregation of a polypeptide comprising the sequence:
2. (1) The amino acid sequence shown in SEQ ID NO: 1, or (2) A modified sequence or fragment having at least 90% sequence identity to the amino acid sequence of positions 2 to 268 of SEQ ID NO: 1 and having adhesive properties for other targets. A composition comprising a peptide comprising or consisting of the amino acid sequence AVL, SVL or ATL, for separating the binding between a polypeptide comprising the above, or a fusion or complex of the polypeptide with another amino acid sequence, and the other target.
3. The composition of claim 2 , wherein the object is a functionality-imparting entity.
4. The composition of claim 2 , wherein the target substance is streptavidin, neutral avidin, or a modified form thereof.
5. The composition of claim 3 , wherein the functionalizing entity is an enzyme, an antibody, a fluorescent molecule, a receptor, an antimicrobial peptide, a signal factor, an inducer, a nucleic acid aptamer, a serum component, or a cell.
6. The composition of any one of claims 1 to 5, wherein the peptide comprises the amino acid sequence AVL, SVL or ATL.
7. The composition according to any one of claims 1 to 6, wherein the peptide has 0, 1, 2, 3, 4, 5, 6, or 7 amino acids added to the N-terminus, C-terminus, or both, of the amino acid sequence AVL, SVL, or ATL.
8. The composition according to any one of claims 1 to 7, wherein the peptide consists of the amino acid sequence AVL, SVL or ATL.
9. The composition of any one of claims 1 to 8, wherein the modified sequence or a fragment thereof comprises an amino acid sequence that is at least 95% or 99% identical to the amino acid sequence of positions 2 to 268 of SEQ ID NO:
1.
10. A peptide comprising or consisting of the amino acid sequence AVL, SVL or ATL, (1) the amino acid sequence set forth in SEQ ID NO: 4, or (2) A modified sequence or fragment having self-aggregation properties, comprising a sequence having at least 90% sequence identity to positions 59 to 325 of SEQ ID NO:
4.
23. Use of a polypeptide comprising:
11. A peptide comprising or consisting of the amino acid sequence AVL, SVL or ATL, (1) the amino acid sequence shown in SEQ ID NO: 1, or (2) A modified sequence or a fragment thereof, which contains a sequence having at least 90% sequence identity to the amino acid sequence of positions 2 to 268 of SEQ ID NO: 1 and has adhesive properties for other targets. Use of said polypeptide comprising the above-mentioned formula (I) or a fusion or complex of said polypeptide with another amino acid sequence to separate the binding between said polypeptide and another target.
12. The use according to claim 11, wherein the object is a functionality-imparting entity.
13. The use according to claim 11, wherein the target substance is streptavidin, neutral avidin or a modified form thereof.
14. The use according to claim 12, wherein the functionalizing entity is an enzyme, an antibody, a fluorescent molecule, a receptor, an antimicrobial peptide, a signal factor, an inducer, a nucleic acid aptamer, a serum component, or a cell.
15. The use according to any one of claims 10 to 14, wherein the peptide comprises the amino acid sequence AVL, SVL or ATL.
16. The use according to any one of claims 10 to 15, wherein the peptide has 0, 1, 2, 3, 4, 5, 6, 7 or more amino acids added to the N-terminus, C-terminus, or both, of the amino acid sequence AVL, SVL, or ATL.
17. The use according to any one of claims 10 to 16, wherein the peptide consists of the amino acid sequence AVL, SVL or ATL.
18. The use according to any one of claims 10 to 17, wherein the modified sequence or a fragment thereof comprises an amino acid sequence which is at least 95% or 99% identical to the amino acid sequence of positions 2 to 268 of SEQ ID NO:1.
Citation Information
Patent Citations
Method and gene for imparting or enhancing nonspecific adherence and / or aggregability to microorganism
WO2009104281A1
Method for immobilizing and releasing microorganism
WO2014156736A1
Hairy bacteria
WO2015030171A1
